Taysha Gene Therapies (TSHA) Accumulated Depreciation & Amortization: 2022-2025
Historic Accumulated Depreciation & Amortization for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $4.4 million.
- Taysha Gene Therapies' Accumulated Depreciation & Amortization rose 12.03% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.9 million, marking a year-over-year increase of 14.84%. This contributed to the annual value of $3.6 million for FY2024, which is 20.31% up from last year.
- Latest data reveals that Taysha Gene Therapies reported Accumulated Depreciation & Amortization of $4.4 million as of Q3 2025, which was up 6.98% from $4.1 million recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Accumulated Depreciation & Amortization peaked at $4.4 million during Q3 2025, and registered a low of $754,000 during Q1 2022.
- In the last 3 years, Taysha Gene Therapies' Accumulated Depreciation & Amortization had a median value of $3.6 million in 2024 and averaged $3.3 million.
- Data for Taysha Gene Therapies' Accumulated Depreciation & Amortization shows a peak YoY soared of 161.67% (in 2023) over the last 5 years.
- Over the past 4 years, Taysha Gene Therapies' Accumulated Depreciation & Amortization (Quarterly) stood at $1.6 million in 2022, then skyrocketed by 81.43% to $3.0 million in 2023, then climbed by 20.31% to $3.6 million in 2024, then rose by 12.03% to $4.4 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $4.4 million for Q3 2025, versus $4.1 million for Q2 2025 and $3.8 million for Q1 2025.